Report: Zhonghui Biotech-B (2627.HK) Exceeds 4000-Fold Oversubscription, Becomes Third-Largest IPO of the Year! 195,000 People Subscribe to Zhonghui Biotech, Raising Up to HK$5.18 Billion

　　Globe Report August 6th ｜ Vaccine company Zhonghui Biotech-B (2627.HK) has ended its subscription today at noon, with news emerging that the public offering part of Zhonghui Biotech's IPO has achieved a staggering 4000-fold oversubscription, involving an amount exceeding HK$21 billion, surpassing this year's May-listed Shangfang Mother (2589.HK), which had a 3616-fold oversubscription, and becoming the third-largest IPO of the year.

　　According to reports, as many as 195,000 people have subscribed to Zhonghui Biotech.

　　Zhonghui Biotech's IPO price per share is HK$12.9-15.5, with a total issue size of 3344.26 million shares, with Hong Kong public offering accounting for 10%, the rest being international allocation, raising up to HK$5.18 billion. One-lot purchase of 200 shares costs HK$3,131.26. The expected listing date is next Monday (11th).